KRRO Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -1.36%, SMA50 20.04%, SMA200 -39.88%). The stock’s 14-day RSI is 51.64 (neutral), while the ATR of 1.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.46% below its high and over 120.58% above its low. Average 10-day trading volume of 167.70 thousand shares is below the 3-month average of 302.35 thousand, indicating normal recent market interest.

Korro Bio, Inc. has 9.39 million shares outstanding. The public float is 5.74 million shares, elevated short interest at 16.70% of float. This equals 1.19 million shares. The short ratio is 9.78 days. Institutional investors hold 103.72% of the float. Insiders own 6.18%. Walker Paul Edward holds 1.09 million shares, Yang Rick has 1.09 million shares and Chang Carmen has 1.09 million shares.

Korro Bio, Inc. generated EPS of -$9.42 over the past year. Five-year average earnings growth is 21.83%. Wall Street analysts project EPS growth of 6.05% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 9 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $147.00 to $7.00. The high target offers 1156.41% upside. The low target suggests -40.17% downside. The mean target is $51.94. This offers 343.93% upside. Korro Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -26.44%. The prior quarter beat by 7.87%. Over the last six quarters, Apple has recorded several small beats. These include 1.25% in August 13, 2024.

Korro Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.02. This means the shares are trading above this model’s fair value.

Korro Bio, Inc. (NASDAQ:KRRO) closed at $11.70 USD, gaining $0.46 (4.14%) from the previous close of $11.23. The stock is currently mid-range between its 52-week high and low $5.20 and $55.89. With a market capitalization of about $110.18 million, Korro Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.44). Key stats such as the average daily volume over the past year has been around 318.27 thousand shares, in line with its 52-week average. Headquartered in Cambridge, MA, Korro Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ram Aiyar, the company employs approximately 112 people and listed since October 03, 2019. Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases.

Korro Bio, Inc. trades at a P/E ratio of -1.24, slightly below the S&P 500 average, with a price-to-sales ratio of 14.87 and a price-to-book ratio of 1.1 suggesting the stock is closer to book value. The P/FCF stands at -1.56, also below market averages.

Our AI price prediction model suggests that Korro Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.71%, with price expected at $13.07 by March 04, 2026, within a range of $12.01 to $14.10 3-Month Outlook: Projected fall of -78.21%, reaching $2.55 by May 19, 2026, with a range of $0.21 to $3.98. 1-Year Outlook: Projected loss of -49.15%, with price at $5.95 by February 18, 2027, within a range of $0.00 to $0.00.

Korro Bio, Inc. (NASDAQ:KRRO) shares are flat 7.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Korro Bio, Inc. trading at a premium to the broader market with a P/E of -1.24. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $66.64, suggesting 469.57% upside. Our AI forecast model points to short-term strength (11.71% over two weeks), a medium-term fall (-78.21% over three months), and a longer-term loss (-49.15% over one year), with expected trading ranges indicating moderate volatility.